AdvaMed Statement on President’s Reciprocal Tariff Pause

WASHINGTON—AdvaMed, the medtech association, called the U.S.-China trade announcement a positive step toward supporting the U.S.-led medtech industry and its service to patients nationwide and globally. 

AdvaMed® Advancements: Q3 2025 Report. Amid an increasingly charged political environment, AdvaMed remained a steady, persuasive voice for medtech innovation. From mobilizing rapid action on the Section 232 investigation to advancing breakthrough coverage legislation. Learn more

Explore AdvaMed’s 2024 Economic Impact Report, developed by Frost & Sullivan, highlighting medtech’s vital contributions to the U.S. economy

WASHINGTON—AdvaMed, the medtech association, today submitted formal comments responding to the U.S. Department of Commerce investigation into whether the U.S.’s current level of medtech imports has national security implications. The comments outlined medtech as an American success story and the United States as the global leader in innovating and making the highest quality medtech for the United States and world, an export powerhouse, and much less reliant on medtech imports than sometimes perceived.

WASHINGTON—AdvaMed, the MedTech Association, released the following statement from President and CEO Scott Whitaker on the Administration’s announcement of its investigation under Section 232 of the Trade Expansion Act into whether the U.S.’s current level of medtech imports has national security implications:

WASHINGTON—AdvaMed, the medtech association, today thanked the U.S. House Energy and Commerce Health Subcommittee for highlighting the need for Medicare coverage of FDA-authorized breakthrough medtech and releasing a discussion draft of breakthrough coverage legislation at a hearing, “Examining Policies to Enhance Seniors’ Access to Breakthrough Medical Technologies.” 

WASHINGTON—AdvaMed, the medtech association, today welcomed U.S. House of Representatives Committee on Ways and Means passage of legislation providing Medicare coverage of FDA-designated and authorized breakthrough medtech. AdvaMed also urged legislators to add diagnostic tests to the measure, the Ensuring Patient Access to Critical Breakthrough Products Act, H.R. 5343. 

WASHINGTON—AdvaMed, the medtech association, welcomed today’s CMS’ announcement of the details of the $50 billion Rural Health Transformation Program. This program gives states the chance to access the latest health care technologies that best suit their needs to improve health outcomes for rural Americans.